Proteon Therapeutics, Inc. (NASDAQ:PRTO)‘s stock had its “market perform” rating reiterated by investment analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Wednesday.

Several other brokerages have also weighed in on PRTO. Cowen and Company reaffirmed a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. HC Wainwright set a $3.00 target price on Proteon Therapeutics and gave the stock a “hold” rating in a research report on Saturday, May 13th. Zacks Investment Research lowered Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Maxim Group set a $6.00 target price on Proteon Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. Proteon Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Shares of Proteon Therapeutics (PRTO) traded up 2.077% during midday trading on Wednesday, hitting $1.327. The stock had a trading volume of 2,762 shares. Proteon Therapeutics has a 12-month low of $1.10 and a 12-month high of $11.45. The stock has a 50-day moving average price of $1.38 and a 200-day moving average price of $1.53. The stock’s market cap is $23.38 million.

Proteon Therapeutics (NASDAQ:PRTO) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.11. Equities analysts forecast that Proteon Therapeutics will post ($1.55) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Proteon Therapeutics’ (PRTO) “Market Perform” Rating Reiterated at Oppenheimer Holdings, Inc.” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at

An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC purchased a new stake in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up approximately 0.2% of RA Capital Management LLC’s holdings, making the stock its 22nd largest position. RA Capital Management LLC owned about 7.59% of Proteon Therapeutics at the end of the most recent quarter. 41.08% of the stock is currently owned by hedge funds and other institutional investors.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with's FREE daily email newsletter.